Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical research trials and A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer clinical trial. Subjects typically recieve the finest healthcare available for their A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer



A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

For Condition: Ovarian Cancer
Status: Recruiting
Sponsor(s): EMD Pharmaceuticals , Merck KGaA
Synopsis: EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR. One type of cancer which frequently contains EGFR is ovarian cancer. This study will test the safety and effects of EMD 72000 in subjects with EGFR-positive recurrent ovarian cancer following standard treatment that has failed.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Open Label, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Recurrent ovarian cancer (including primary peritoneal cancer) following treatment (e.g., doxorubicin HCL liposome, topotecan, etc.) for primary or secondary platinum-refractory disease - Immunohistochemical evidence of tumor EGFR (HER-1) expression - At least one measurable lesion according to the WHO criteria - Life expectancy 12 weeks - ECOG performance status 0-1 Exclusion Criteria: - History of prior MAb therapy - History of prior treatment with an EGFR (HER-1) directed therapy - Known brain metastases - Presence of a Grade 2 pre-existing skin disorder (alopecia is permitted) - Known intercurrent infections or immunosuppression - Actively infected with, or chronic carriers of HBV - Evidence of HCV disease - Previous diagnosis of autoimmune disease - Known hypersensitivity to the administered drugs or any of their components - Receipt of chemotherapy, radiation therapy, or another investigational drug within 30 days of enrollment
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:  EMD 72000-030; 
Study Start Date: 
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073541

Other Ovarian Cancer Studies:
1. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833

2. A Study to Evaluate the Safety and Effect of Pertuzumab on Cancerous Lesions in Women with Advanced, Refractory or Recurrent Ovarian Cancer

3. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

4. Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

5. PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Related Studies:

Other Ovarian Cancer Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials

A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer
Modify your Search

  Other Ovarian Cancer Clinical Trials
  Other Maryland Clinical Trials
  Other Baltimore Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103